Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | PBK | Q96KB5 | 3/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221703 | 1.00 | ADRB1 (0.59) | ADRB1SCN9AHDAC4HDAC6PBK | |
| SCHEMBL5088410 | 0.95 | ADRB1 (0.60) | ADRB1SCN9AHDAC4HDAC6PBK | |
| SCHEMBL31188482 | 0.95 | ADRB1 (0.60) | ADRB1SCN9AHDAC4HDAC6PBK | |
| SCHEMBL8274391 | 0.95 | ADRB1 (0.60) | ADRB1SCN9AHDAC4HDAC6PBK | |
| SCHEMBL20344080 | 0.87 | SCN9A (0.60) | SCN9AHDAC4HDAC6PBKPARP1 | |
| SCHEMBL3037871 | 0.86 | SCN9A (0.58) | SCN9AHDAC4HDAC6PBKIKBKB | |
| SCHEMBL20344016 | 0.86 | SCN9A (0.58) | SCN9AHDAC4HDAC6PBKOPRM1 | |
| SCHEMBL6221777 | 0.86 | SCN9A (0.61) | SCN9AHDAC4HDAC6PBKOPRM1 | |
| SCHEMBL3040633 | 0.86 | SCN9A (0.56) | ADRB1SCN9AHDAC4HDAC6PBK | |
| SCHEMBL17888386 | 0.86 | SCN9A (0.58) | SCN9AHDAC4HDAC6PBKHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| US-10406146-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20180263967-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-20 | — | — | US | disclosed |
| EP-3342772-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-07-04 | — | — | EP | disclosed |
| CN-106928126-A | A kind of amide derivatives and preparation method thereof and application pharmaceutically | 四川海思科制药有限公司 | 2017-07-07 | — | — | CN | disclosed |
| CN-103819416-A | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | EXELIXIS INC | 2014-05-28 | — | — | CN | disclosed |
| EP-2139483-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| CN-101282948-A | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | EXELIXIS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| US-6677354-B2 | TREATING SLEEP, BRAIN, SEXUAL, CARDIOVASCULAR, NERVOUS SYSTEM, PSYCHOLOGICAL, GLANDULAR, AND GASTROINTESTINAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-13 | — | — | US | disclosed |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-02 | — | — | US | disclosed |
| EP-1289955-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096302-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-12-20 | — | — | WO | disclosed |
| US-4952574-A | Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides | RIKER LABORATORIES, INC. (US) | 1990-08-28 | — | — | US | disclosed |
| US-4952574-A | Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides | RIKER LABORATORIES, INC. (US) | 1990-08-28 | — | — | US | disclosed |
| US-4952574-A | Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides | RIKER LABORATORIES, INC. (US) | 1990-08-28 | — | — | US | disclosed |
| US-4097481-A | ANTIARRHYTHMIC AGENTS | RIKER LABORATORIES, INC. (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10406146-B2 | Heterocyclic compound | HDAC1, HDAC5, HDAC11 | ADRB1 2225/4885SCN9A 2494/4885HDAC4 6/4885 |
| US-20180263967-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC5, HDAC11 | ADRB1 2225/4885SCN9A 2494/4885HDAC4 6/4885 |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | HCRTR2, HCRTR1, NPSR1 | ADRB1 50/4885SCN9A 218/4885HDAC4 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.